Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy

Ospedale Policlinico San Martino

Status

Unknown

Conditions

Uterine Fibroids

Uterine Myomas

Treatments

Procedure: Operative hysteroscopy

Behavioral: Anamnesis

Diagnostic Test: Transvaginal ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT04400942

NOM-MYOMA RES

Details and patient eligibility

About

The aim of this observational retrospective analysis is to evaluate predictive factors for complete myoma resection during hysteroscopic myomectomy for developing and validating a nomogram.

This tool can help clinicians to support the patient in making an informed decision about therapeutic options for uterine submucous myomas by defining risk factors predicting a high complexity myomectomy.

Full description

Overall, 10% of all uterine myomas are submucosal. These myomas spread into the uterine cavity, lifting the endometrial mucosa, and are a common cause of abnormal uterine bleeding, dysmenorrhea, early miscarriage and they may be a cause of infertility.

Hysteroscopic myomectomy is the surgical procedure of choice for the treatment of submucosal myomas, because it is minimally invasive and has the advantage of preserving the integrity of the uterine wall.

The characteristics of the myomas (size, number and location) enables the surgeon to choose the surgical approach that will provide the best outcome for the patient, and may predict the chances of a complete hysteroscopic resection of myomas in one procedure.

Enrollment

600 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with ultrasonographic diagnosis of uterine myomas

Exclusion criteria

patients with previous incomplete hysteroscopic myoma resection;
patients undergoing additional surgical procedures performed by hysteroscopy (such as, resection of endometrial polyps);
patients undergoing associated non-hysteroscopic surgical procedures;
patients with severe cardiovascular disease, decompensated diabetes and severe hematologic disorders